[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fhC2hT4X1k_kfoUgWzAJ7quDW1Vxj-pGj_DI4YYIDlqo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"California Pacific Medical Center Research Institute",[4],39,false,3,0,13532,1,17,[14,17,19,22,24,26,28,30],{"name":15,"count":16},"Metastatic Melanoma",4,{"name":18,"count":8},"Methamphetamine Dependence",{"name":20,"count":21},"Methamphetamine Addiction",2,{"name":23,"count":11},"Chronic Insomnia",{"name":25,"count":11},"Disorders of Gallbladder",{"name":27,"count":11},"Disorders of Biliary Tract",{"name":29,"count":11},"MDMA Discontinuation Syndrome",{"name":31,"count":11},"Chronic Hepatitis B Virus",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT03924414","Trial of Parkinson's And Zoledronic Acid","2025-10-31","Zoledronic Acid 5Mg\u002FBag 100Ml Inj",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,76,102,120,143,168,214,238,262,288,313,338,356,381,406,431,449,475,498,521,544,568,592,616],{"intervention":37,"totalTrials":11,"cells":47},{"EARLY_PHASE1":48,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":56,"NA":74},{"trials":49,"activeCount":9},[],{"trials":51,"activeCount":9},[],{"trials":53,"activeCount":9},[],{"trials":55,"activeCount":9},[],{"trials":57,"activeCount":11,"soonestReadout":36},[58],{"nctId":34,"briefTitle":35,"status":59,"phases":60,"primaryCompletion":36,"completion":36,"start":61,"enrollment":62,"conditions":63,"interventions":73},"ACTIVE_NOT_RECRUITING",[43],"2019-11-15",2650,[64,65,66,67,68,69,70,71,72],"Parkinson Disease","Osteoporosis","Parkinsonism","Parkinson's Disease and Parkinsonism","Atypical Parkinsonism","Progressive Supranuclear Palsy","Multiple System Atrophy","Vascular Parkinsonism","Dementia With Lewy Bodies",[37],{"trials":75,"activeCount":9},[],{"intervention":77,"totalTrials":11,"cells":78},"Zolpidem",{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":87,"NA":100},{"trials":80,"activeCount":9},[],{"trials":82,"activeCount":9},[],{"trials":84,"activeCount":9},[],{"trials":86,"activeCount":9},[],{"trials":88,"activeCount":9},[89],{"nctId":90,"briefTitle":91,"status":92,"phases":93,"primaryCompletion":94,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":98},"NCT04468776","CBT-I or Zolpidem\u002FTrazodone for Insomnia","COMPLETED",[43],"2024-06-30","2022-02-25",155,[23],[77,99],"Trazodone",{"trials":101,"activeCount":9},[],{"intervention":99,"totalTrials":11,"cells":103},{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":118},{"trials":105,"activeCount":9},[],{"trials":107,"activeCount":9},[],{"trials":109,"activeCount":9},[],{"trials":111,"activeCount":9},[],{"trials":113,"activeCount":9},[114],{"nctId":90,"briefTitle":91,"status":92,"phases":115,"primaryCompletion":94,"completion":94,"start":95,"enrollment":96,"conditions":116,"interventions":117},[43],[23],[77,99],{"trials":119,"activeCount":9},[],{"intervention":121,"totalTrials":11,"cells":122},"A single oral 5 mg of duterium labeled methamphetamine",{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":141},{"trials":124,"activeCount":9},[],{"trials":126,"activeCount":9},[],{"trials":128,"activeCount":9},[],{"trials":130,"activeCount":9},[],{"trials":132,"activeCount":9},[133],{"nctId":134,"briefTitle":135,"status":136,"phases":137,"enrollment":9,"conditions":138,"interventions":140},"NCT01529892","The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine","WITHDRAWN",[43],[139],"Methamphetamine Metabolism, CYP2D6 Genotype",[121],{"trials":142,"activeCount":9},[],{"intervention":144,"totalTrials":11,"cells":145},"sirolimus",{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":166},{"trials":147,"activeCount":9},[],{"trials":149,"activeCount":9},[],{"trials":151,"activeCount":9},[],{"trials":153,"activeCount":9},[],{"trials":155,"activeCount":9},[156],{"nctId":157,"briefTitle":158,"status":92,"phases":159,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":165},"NCT00713284","Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic",[43],"2010-11","2007-05",29,[164],"Renal Transplantation",[144],{"trials":167,"activeCount":9},[],{"intervention":169,"totalTrials":8,"cells":170},"modafinil",{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":208,"PHASE4":210,"NA":212},{"trials":172,"activeCount":9},[],{"trials":174,"activeCount":9},[],{"trials":176,"activeCount":9},[177,187,197],{"nctId":178,"briefTitle":179,"status":92,"phases":180,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":186},"NCT00538655","A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence",[41],"2009-01","2011-06","2008-01",20,[20],[169],{"nctId":188,"briefTitle":189,"status":92,"phases":190,"primaryCompletion":191,"start":192,"enrollment":193,"conditions":194,"interventions":195},"NCT01354470","A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence",[41],"2013-02","2011-10",72,[18],[196],"Modafinil",{"nctId":198,"briefTitle":199,"status":200,"phases":201,"primaryCompletion":182,"completion":182,"start":202,"enrollment":203,"conditions":204,"interventions":207},"NCT00630097","A Dose Ranging Study of Modafinil for Methamphetamine Dependence","UNKNOWN",[41],"2009-12",90,[205,206],"Substance Dependence","Amphetamine Dependence",[169],{"trials":209,"activeCount":9},[],{"trials":211,"activeCount":9},[],{"trials":213,"activeCount":9},[],{"intervention":215,"totalTrials":11,"cells":216},"Sutent",{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":232,"PHASE4":234,"NA":236},{"trials":218,"activeCount":9},[],{"trials":220,"activeCount":9},[],{"trials":222,"activeCount":9},[223],{"nctId":224,"briefTitle":225,"status":92,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":231},"NCT00631618","Clinical Trial of Sutent to Treat Metastatic Melanoma",[41],"2012-03","2007-09",12,[15],[215],{"trials":233,"activeCount":9},[],{"trials":235,"activeCount":9},[],{"trials":237,"activeCount":9},[],{"intervention":239,"totalTrials":11,"cells":240},"Biochemo + bevacizumab then ipilimumab",{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":256,"PHASE4":258,"NA":260},{"trials":242,"activeCount":9},[],{"trials":244,"activeCount":9},[],{"trials":246,"activeCount":9},[247],{"nctId":248,"briefTitle":249,"status":92,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":255},"NCT01743157","Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma",[40,41],"2013-05","2010-12",24,[15],[239],{"trials":257,"activeCount":9},[],{"trials":259,"activeCount":9},[],{"trials":261,"activeCount":9},[],{"intervention":263,"totalTrials":11,"cells":264},"Immunotherapy",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":282,"PHASE4":284,"NA":286},{"trials":266,"activeCount":9},[],{"trials":268,"activeCount":9},[],{"trials":270,"activeCount":9},[271],{"nctId":272,"briefTitle":273,"status":200,"phases":274,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":281},"NCT05077280","A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma",[41],"2024-03","2026-03","2021-09-20",40,[280],"Uveal Melanoma",[263],{"trials":283,"activeCount":9},[],{"trials":285,"activeCount":9},[],{"trials":287,"activeCount":9},[],{"intervention":289,"totalTrials":11,"cells":290},"Naltrexone",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":307,"PHASE4":309,"NA":311},{"trials":292,"activeCount":9},[],{"trials":294,"activeCount":9},[],{"trials":296,"activeCount":9},[297],{"nctId":298,"briefTitle":299,"status":92,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":306},"NCT00984360","Study of Naltrexone for Methamphetamine Addiction",[41],"2011-07","2012-09","2009-09",22,[18],[289],{"trials":308,"activeCount":9},[],{"trials":310,"activeCount":9},[],{"trials":312,"activeCount":9},[],{"intervention":314,"totalTrials":11,"cells":315},"sunitinib",{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":332,"PHASE4":334,"NA":336},{"trials":317,"activeCount":9},[],{"trials":319,"activeCount":9},[],{"trials":321,"activeCount":9},[322],{"nctId":323,"briefTitle":324,"status":136,"phases":325,"primaryCompletion":326,"completion":326,"start":327,"enrollment":9,"conditions":328,"interventions":330},"NCT02400385","A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma",[41],"2015-12","2014-10",[329],"Melanoma",[314,331],"nivolumab",{"trials":333,"activeCount":9},[],{"trials":335,"activeCount":9},[],{"trials":337,"activeCount":9},[],{"intervention":331,"totalTrials":11,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":350,"PHASE4":352,"NA":354},{"trials":341,"activeCount":9},[],{"trials":343,"activeCount":9},[],{"trials":345,"activeCount":9},[346],{"nctId":323,"briefTitle":324,"status":136,"phases":347,"primaryCompletion":326,"completion":326,"start":327,"enrollment":9,"conditions":348,"interventions":349},[41],[329],[314,331],{"trials":351,"activeCount":9},[],{"trials":353,"activeCount":9},[],{"trials":355,"activeCount":9},[],{"intervention":357,"totalTrials":11,"cells":358},"Niraparib",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":360,"activeCount":9},[],{"trials":362,"activeCount":9},[],{"trials":364,"activeCount":9},[365],{"nctId":366,"briefTitle":367,"status":200,"phases":368,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":374},"NCT03925350","Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation",[41],"2022-02","2023-02","2019-03-20",41,[15],[357],{"trials":376,"activeCount":9},[],{"trials":378,"activeCount":9},[],{"trials":380,"activeCount":9},[],{"intervention":382,"totalTrials":11,"cells":383},"Dextroamphetamine",{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":400,"PHASE4":402,"NA":404},{"trials":385,"activeCount":9},[],{"trials":387,"activeCount":9},[],{"trials":389,"activeCount":9},[390],{"nctId":391,"briefTitle":392,"status":92,"phases":393,"primaryCompletion":394,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":399},"NCT00630682","A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence",[41],"2009-03","2011-08","2006-09",60,[20],[382],{"trials":401,"activeCount":9},[],{"trials":403,"activeCount":9},[],{"trials":405,"activeCount":9},[],{"intervention":407,"totalTrials":11,"cells":408},"Olaparib",{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":425,"PHASE4":427,"NA":429},{"trials":410,"activeCount":9},[],{"trials":412,"activeCount":9},[],{"trials":414,"activeCount":9},[415],{"nctId":416,"briefTitle":417,"status":200,"phases":418,"primaryCompletion":419,"completion":420,"start":421,"enrollment":372,"conditions":422,"interventions":423},"NCT04633902","Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation",[41],"2023-06-30","2024-12-31","2021-03-03",[15],[407,424],"Pembrolizumab",{"trials":426,"activeCount":9},[],{"trials":428,"activeCount":9},[],{"trials":430,"activeCount":9},[],{"intervention":424,"totalTrials":11,"cells":432},{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":443,"PHASE4":445,"NA":447},{"trials":434,"activeCount":9},[],{"trials":436,"activeCount":9},[],{"trials":438,"activeCount":9},[439],{"nctId":416,"briefTitle":417,"status":200,"phases":440,"primaryCompletion":419,"completion":420,"start":421,"enrollment":372,"conditions":441,"interventions":442},[41],[15],[407,424],{"trials":444,"activeCount":9},[],{"trials":446,"activeCount":9},[],{"trials":448,"activeCount":9},[],{"intervention":450,"totalTrials":11,"cells":451},"Rituximab",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":467,"PHASE3":469,"PHASE4":471,"NA":473},{"trials":453,"activeCount":9},[],{"trials":455,"activeCount":9},[456],{"nctId":457,"briefTitle":458,"status":92,"phases":459,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":466},"NCT00259805","A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis",[40],"2008-12","2005-01",10,[464,465],"Chronic Focal Encephalitis","Rasmussen's Encephalitis",[450],{"trials":468,"activeCount":9},[],{"trials":470,"activeCount":9},[],{"trials":472,"activeCount":9},[],{"trials":474,"activeCount":9},[],{"intervention":476,"totalTrials":11,"cells":477},"6β-Naltrexol escalating doses from 0.05-0.5 mg IV",{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":490,"PHASE3":492,"PHASE4":494,"NA":496},{"trials":479,"activeCount":9},[],{"trials":481,"activeCount":9},[482],{"nctId":483,"briefTitle":484,"status":92,"phases":485,"primaryCompletion":303,"completion":303,"start":394,"enrollment":486,"conditions":487,"interventions":489},"NCT00829777","Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects",[40],8,[488],"Opiate Addiction",[476],{"trials":491,"activeCount":9},[],{"trials":493,"activeCount":9},[],{"trials":495,"activeCount":9},[],{"trials":497,"activeCount":9},[],{"intervention":499,"totalTrials":11,"cells":500},"3,4-methylenedioxymethamphetamine or Placebo",{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":502,"activeCount":9},[],{"trials":504,"activeCount":9},[],{"trials":506,"activeCount":9},[],{"trials":508,"activeCount":9},[],{"trials":510,"activeCount":9},[],{"trials":512,"activeCount":9},[513],{"nctId":514,"briefTitle":515,"status":92,"phases":516,"primaryCompletion":252,"completion":517,"start":518,"enrollment":229,"conditions":519,"interventions":520},"NCT01053403","Study of the Effects of MDMA\u002FEcstasy on Water Regulation, Sleep, and Cognition.",[44],"2011-02","2010-04",[29],[499],{"intervention":522,"totalTrials":11,"cells":523},"MDA",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":525,"activeCount":9},[],{"trials":527,"activeCount":9},[],{"trials":529,"activeCount":9},[],{"trials":531,"activeCount":9},[],{"trials":533,"activeCount":9},[],{"trials":535,"activeCount":9},[536],{"nctId":537,"briefTitle":538,"status":92,"phases":539,"primaryCompletion":540,"completion":540,"start":181,"enrollment":229,"conditions":541,"interventions":543},"NCT00823407","Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]",[44],"2009-07",[542],"Healthy",[522],{"intervention":545,"totalTrials":11,"cells":546},"MDMA and citalopram",{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":548,"activeCount":9},[],{"trials":550,"activeCount":9},[],{"trials":552,"activeCount":9},[],{"trials":554,"activeCount":9},[],{"trials":556,"activeCount":9},[],{"trials":558,"activeCount":9},[559],{"nctId":560,"briefTitle":561,"status":92,"phases":562,"primaryCompletion":202,"completion":395,"start":563,"enrollment":564,"conditions":565,"interventions":567},"NCT00838305","Role of Serotonin in Acute and Subacute MDMA Effects",[44],"2009-02",13,[566],"MDMA Mechanism of Action",[545],{"intervention":569,"totalTrials":11,"cells":570},"Salvinorin A",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":581},{"trials":572,"activeCount":9},[],{"trials":574,"activeCount":9},[],{"trials":576,"activeCount":9},[],{"trials":578,"activeCount":9},[],{"trials":580,"activeCount":9},[],{"trials":582,"activeCount":9},[583],{"nctId":584,"briefTitle":585,"status":92,"phases":586,"primaryCompletion":202,"completion":587,"start":588,"enrollment":486,"conditions":589,"interventions":591},"NCT01149824","Placebo Controlled Study of Sublingual Salvinorin A",[44],"2010-10","2009-06",[590],"Pharmaceutical Preparations",[569],{"intervention":593,"totalTrials":11,"cells":594},"l-methamphetamine",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":596,"activeCount":9},[],{"trials":598,"activeCount":9},[],{"trials":600,"activeCount":9},[],{"trials":602,"activeCount":9},[],{"trials":604,"activeCount":9},[],{"trials":606,"activeCount":9},[607],{"nctId":608,"briefTitle":609,"status":92,"phases":610,"primaryCompletion":303,"completion":303,"start":611,"enrollment":229,"conditions":612,"interventions":614},"NCT00829634","Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation",[44],"2008-10",[613],"Nasal Congestion",[593,615],"d-methamphetamine",{"intervention":615,"totalTrials":11,"cells":617},{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":626,"NA":628},{"trials":619,"activeCount":9},[],{"trials":621,"activeCount":9},[],{"trials":623,"activeCount":9},[],{"trials":625,"activeCount":9},[],{"trials":627,"activeCount":9},[],{"trials":629,"activeCount":9},[630],{"nctId":608,"briefTitle":609,"status":92,"phases":631,"primaryCompletion":303,"completion":303,"start":611,"enrollment":229,"conditions":632,"interventions":633},[44],[613],[593,615]]